TMCnet News
Generex Issues Clarification on Stock Dividends
MIRAMAR, Fla., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today clarified certain information regarding its stock dividends consisting of two shares of Generex stock for every five shares held, and two shares of NuGenerex Immuno-Oncology for every five shares of Generex. These are two separate dividends. Information in our previous press release discussing the ex-dividend date and ramifications of the ex-dividend date apply only to the dividend of Generex shares. There is no Ex-Dividend Date for the NuGenerex Immuno-Oncology shares because those shares do not trade. The payment date for the NuGenerex Immuno-Oncology shares was February 24, and the market effective date is today. Joe Moscato, President & CEO of Generex, said, “I understand there have been several questions from brokers and shareholders on this issue, and hope this clarifies it for everyone. In addition, now that the dividend is finally paid after many attempts, our next big initiative is to file the S1 for NGIO and take it public directly to the Nasdaqstock exchange, unlock its value, as well as close AltuCell. We continue the negotiations with our Chinese partnered agreements for our Coronavirus Vaccine initiative, we have our Chinese visas from our official invitations from our potential Chinese partners and are ready to go to China once we are finalized on our contract." About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. Cautionary Note Regarding Forward-Looking Statements Generex Contact: Joseph Moscato Todd Falls |